Going forward..., page-2

Agreed, pfeifer. How many times have we seen innovative science completely let down by mediocre custodianship by managers?

Bad negotiators, self interest selling out too early or living the high life, failure to build competitive tension, fixated on one buyer, lack of partnerships, not investing themselves, failure to see the need for ongoing scientific validation, inability to get into the top tier of big pharma. I hope this isnt the case here but some of the behaviours have me worried.

The team have it in their hands now with the GVHD outcome to have our CYP MSCs accepted as the standard for all MSC related research and consequently products.

How they play the next 6 months is critical to establishing higher multiples market cap wise.